The American Society of Clinical Oncology (ASCO®) and Conexiant today announced that ASCO AI in Oncologyis the premier digital destination designed to help oncology professionals navigate the transformative role of artificial intelligence (AI) in cancer care. The launch of this initiative marks the second major collaboration between the two organizations following years of success. ASCO postEstablished in 2010.
As AI technology rapidly changes medical practice, ASCO AI in Oncology serves as an educational platform of trusted research and up-to-date information to help providers stay prepared and confident.
ASCO AI in Oncology Planned content pillars:
- Trustworthy intelligence: Expert-driven insights prioritize clinical relevance and curated from authoritative sources.
- Practical education: Content focused on how AI tools can improve diagnostic accuracy, streamline workflows, and personalize treatment pathways.
- Community perspective: A collaborative environment where oncology clinicians and researchers from around the world can connect across specialties and institutions and share real-world implementation experiences.
The platform includes in-depth clinical analysis, as well as practitioner commentary and interactive programs designed to foster professional development. Collectively, these tools are designed to help clinicians leverage AI for clinical success.
“AI is transforming cancer care at an incredible rate, but the amount of noise within the AI space can be distracting and confusing. This resource cuts through that noise by providing valuable insights directly from trusted oncology experts.” ASCO Chief Executive Officer said: Dr. Clifford Hudis, FACP, FASCO. “By translating these insights into actionable tips, clinicians can confidently use AI to prioritize what matters most: patient outcomes.”
The partnership with Conexiant represents another major step in ASCO’s broader efforts to responsibly harness the power of AI to support oncology professionals and improve cancer care.
